Eosinophil-rich Linear IgA Bullous Dermatosis: A Case Report of a Rare Entity
Main Article Content
Keywords
Linear IgA Bullous Dermatosis, Eosinophils, Neutrophils, Direct Immunofluorescence, Bullous Diseases
Abstract
Linear IgA bullous dermatosis (LABD) is an uncommon autoimmune bullous disease characterized by a subepidermal neutrophilic infiltrate. It classically presents as widespread tense vesicles in an annular pattern and is defined by the presence of linear deposition of IgA at the dermal-epidermal junction. Eosinophil-rich LABD has been rarely reported in the literature, including in association with COVID-19 booster vaccination, parvovirus B19 infection, hematologic malignancies, and drug-induced LABD. The varied clinical and histopathologic findings often make it difficult to differentiate LABD from other blistering diseases such as bullous pemphigoid and dermatitis herpetiformis. For this reason, immunofluorescence and serologic testing are critical for identifying the underlying diagnosis.
References
2. García-Gil MF, Franco Rubio JI, Álvarez-Salafranca M, Monte Serrano J, Prieto-Torres L. Flame figures in linear immunoglobulin A bullous dermatosis secondary to parvovirus B19 infection. Am J Dermatopathol. 2021;43(1):60-62. doi: 10.1097/DAD.0000000000001690
3. Garel B, Ingen-Housz-Oro S, Afriat D, et al. Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. Br J Clin Pharmacol. 2019;85(3):570-579. doi:10.1111/bcp.13827
4. Andriano TM, Tannenbaum R, Xu H, Magro CM. Linear IgA bullous dermatosis in the setting of angioimmunoblastic T-cell lymphoma. J Cutan Pathol. 2023;50(1):43-46. doi:10.1111/cup.14309
5. Colmant C, Camboni A, Dekeuleneer V, Marot L, Dachelet C, Baeck M. Linear IgA dermatosis in association with angioimmunoblastic T-cell lymphoma infiltrating the skin: A case report with literature review. J Cutan Pathol. 2020;47(3):251-256. doi:10.1111/cup.13576
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.